Seeing red: Flushing out instigators of niacin-associated skin toxicity

Journal of Clinical Investigation

Volumn 120, Issue 8, 2010, Pages 2651-2655

  Dunbar, Richard L ^a,b   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID; FUMARIC ACID DERIVATIVE; FUMARIC ACID METHYL ESTER; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPID; NICOTINIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSLIPIDEMIA; EOSINOPHILIA; ERYTHEMA; FLUSHING; HEART INFARCTION; HUMAN; HYPEREMIA; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; KERATINOCYTE; LANGERHANS CELL; LYMPHOCYTOPENIA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN TOXICITY; SYMPTOM; VASODILATATION;

CYCLOOXYGENASE 2; DYSLIPIDEMIAS; FLUSHING; FUMARATES; HUMANS; MYOCARDIAL INFARCTION; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SKIN;

EID: 77955302309     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44098     Document Type: Note

References (22)

1. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94-114.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
3. Wise A, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278(11):9869-9874.
4. Tunaru S, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9(3):352-355.
5. Soga T, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303(1):364-369.
6. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a metaanalysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185-197.
7. Lai E, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008;2(5):375-383.
8. Basketter DA, Wilhelm KP. Studies on non-immune immediate contact reactions in an unselected population. Contact Derm. 1996;35(4):237-240.
9. English JS, Winkelmann RK, Louback JB, Greaves MW, MacDonald DM. The cellular inflammatory response in nicotinate skin reactions. Br J Dermatol. 1987;116(3):341-349.
10. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126(12):2637-2646.
11. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79-106.
12. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70(6):1844-1849.
13. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis. 2007;192(2):253-258.
14. Papaliodis D, et al. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther. 2008;327(3):665-672.
15. Lai E, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther. 2007;81(6):849-857.
16. Benyo Z, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115(12):3634-3640.
17. Hanson J, et al. Nicotinic acid- and monomethyl fumarate - induced flushing involves GPR109A expressed by keratinocytes and COX-2 - dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910-2919.
18. Tang H, Lu JY-L, Zheng X, Yang Y, Reagan JD. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008;375(4):562-565.
19. Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol. 2010;162(2):427-434.
20. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14):1735-1741. (Pubitemid 44547793)
21. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
22. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.